SELLAS Life Sciences Group (SLS) Stock Forecast & Price Target

$1.17

+0.01 (+0.86%)

(As of 07/26/2024 ET)

SELLAS Life Sciences Group - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy
Based on 1 Analyst Ratings

Based on 1 Wall Street analysts who have issued ratings for SELLAS Life Sciences Group in the last 12 months, the stock has a consensus rating of "Buy." Out of the 1 analysts, 1 has given a buy rating for SLS.

Consensus Price Target

$3.00
156.41% Upside

High Forecast	$3.00
Average Forecast	$3.00
Low Forecast	$3.00

According to the 1 analysts' twelve-month price targets for SELLAS Life Sciences Group, the average price target is $3.00. The highest price target for SLS is $3.00, while the lowest price target for SLS is $3.00. The average price target represents a forecasted upside of 156.41% from the current price of $1.17.

Type	Current Forecast 7/27/23 to 7/26/24	1 Month Ago 6/27/23 to 6/26/24	3 Months Ago 4/28/23 to 4/27/24	1 Year Ago 7/27/22 to 7/27/23
Consensus Rating	Buy	Buy	Buy	Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	1 Buy rating(s)	1 Buy rating(s)	1 Buy rating(s)	2 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$3.00	$3.00	$3.00	$8.00
Forecasted Upside	156.41% Upside	200.00% Upside	200.00% Upside	213.73% Upside

Get SELLAS Life Sciences Group Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for SLS and its competitors with MarketBeat's FREE daily newsletter.

Ad Porter & Company

Obama wins Presidential debate

When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happen, that the 22nd Amendment makes it impossible. But as I explained on live radio years ago, “he could have a proxy… while he remains in control of the administration much like Putin did in Russia.”

Please, watch this now before it’s too late.

SLS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

SLS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

SELLAS Life Sciences Group Stock vs. The Competition

Type	SELLAS Life Sciences Group	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.72	2.50
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	156.41% Upside	3,123.18% Upside	9.15% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
6/24/2024	Royal Bank of Canada 4 of 5 stars	S. Crittenden Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Moderate Buy
11/22/2023	Cantor Fitzgerald 3 of 5 stars		Reiterated Rating	Overweight ➝ Overweight	$3.00	+200.00%
4/18/2023	National Bank Financial 5 of 5 stars	S. Nagle Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform-Speculative
11/15/2022	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy	$14.00 ➝ $8.00	+213.72%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 09:33 PM ET.

SLS Forecast - Frequently Asked Questions

What is SELLAS Life Sciences Group's forecast for 2024?: According to the research reports of 1 Wall Street equities research analysts, the average twelve-month stock price forecast for SELLAS Life Sciences Group is $3.00, with a high forecast of $3.00 and a low forecast of $3.00.
Should I buy or sell SELLAS Life Sciences Group stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SELLAS Life Sciences Group in the last twelve months. There is currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" SLS shares.
Does SELLAS Life Sciences Group's stock price have much upside?: According to analysts, SELLAS Life Sciences Group's stock has a predicted upside of 200.00% based on their 12-month stock forecasts.
Has SELLAS Life Sciences Group been upgraded by Wall Street analysts recently?: Over the previous 90 days, SELLAS Life Sciences Group's stock had 1 upgrade by analysts.
What analysts cover SELLAS Life Sciences Group?: SELLAS Life Sciences Group has been rated by research analysts at Royal Bank of Canada in the past 90 days.
Do Wall Street analysts like SELLAS Life Sciences Group more than its competitors?: Analysts like SELLAS Life Sciences Group more than other "medical" companies. The consensus rating for SELLAS Life Sciences Group is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how SLS compares to other companies.